Slides
Page 1
E A R N I N G S P R E S E N T A T I O N J A N U A R Y 2 0 2 6 www.acutaas.com www.acutaas.com
Page 2
Earnings Presentation | January 2026 Management Commentary 2 Mr. Naresh Patel Executive Chairman and Managing Director Revenue for Q3 FY26 ₹3,932 YoY 43.0% (Mn.) EBITDA for Q3 FY26 ₹1,507 YoY 119.4% PAT for Q3 FY26 ₹1,062 YoY 133.7% “We continue to reinforce our core pharmaceutical intermediates business through the addition of CMO/CDMO opportunities alongside strengthening our business foundation by scaling battery chemicals and semiconductor chemicals verticals. These businesses, which are currently under active capital investment, are progressing steadily toward scale. Over the next three years, we expect each vertical to operate as an independent, self-sustaining growth engine, contributing meaningfully to our overall topline. I am pleased to share that we have sustained strong growth momentum in Q3, driven by the continued ramp-up of our CDMO business. As we progress toward the end of the financial year, supported by a healthy order book and improved visibility, we are revising our revenue growth guidance upward—from 25% to approximately 30%.”
Page 3
Earnings Presentation | January 2026 Q3 FY26 Financial Performance – Key Metrics 3 Revenue from Operations Q3 FY26 Earnings & Business Highlights 2,389 361 2,750 3,511 421 3,932 Advance Intermediates Specialty Chemicals Total Q3FY25 Q3FY26 EBITDA & EBITDA Margin PAT (₹ Mn.) (₹ Mn.)(₹ Mn) 687 1,507 25.0% 38.3% Q3FY25 Q3FY26 EBITDA EBITDA Margin 454 1,062 16.5% 27.0% Q3FY25 Q3FY26 PAT PAT Margin 47.0% 16.5% 43.0% YoY Growth Robust growth in Advanced Pharmaceutical Intermediates business supported by strong Ramp up in CDMO, with specialty chemicals business growing steadily Cost improvement measures and favorable product mix resulted in higher gross margins. This coupled with operating leverage contributed to strong EBITDA for the quarter Robust EBITDA margins, led to a highest ever PAT for the quarter
Page 4
Earnings Presentation | January 2026 Q3 FY26 Financial Performance – P&L Statement 4 Particulars (₹ Mn) Q3EY26 Q3FY25 YoY Q2FY26 QoQ 9MFY26 9MFY25 YoY Revenue from Operations 3,932 2,750 43.0% 3,062 28.4% 9,066 6,984 29.8% COGS 1,692 1,478 1,355 4,015 3,897 Gross Profit 2,240 1,272 76.1% 1,707 31.2% 5,051 3,087 63.6% Gross Margin 57.0% 46.2% 55.8% 55.7% 44.2% Employee benefits expenses 299 217 294 843 604 Other expenses 435 368 461 1,239 1,012 Total Expenses 2,425 2,063 17.5% 2,109 15.0% 6,097 5,513 10.6% EBITDA 1,507 687 119.4% 953 58.1% 2,969 1,471 101.8% EBITDA Margin 38.3% 25.0% 31.1% 32.7% 21.1% Depreciation and amortization 98 63 84 264 193 PBIT 1,408 623 125.9% 869 62.0% 2,705 1,278 111.7% Finance costs 9 7 6 21 56 Other Income 47 17 98 305 112 PBT 1,447 633 128.4% 962 2,989 1,333 124.2% Tax Expense 385 179 243 768 356 PAT 1,062 454 133.7% 719 47.8% 2,221 977 127.3% PAT Margin 27.0% 16.5% 23.5% 24.5% 14.0%
Page 5
Earnings Presentation | January 2026 Financial Performance over the years – Key Metrics 5 Revenue from Operations- Growth Trends 2,322 74 2,396 3,240 166 3,406 4,270 932 5,201 5,180 990 6,170 5,678 1,497 7,175 8,540 1,529 10,069 7,812 1,254 9,066 Advance Intermediates Chemicals Total FY20 FY21 FY22 FY23 FY24 FY25 9MFY26 (₹ Mn.) 29.8% 83.2% 33.3% FY20-25 CAGR: #ROE and ROCE adjusted for Cash & Cash Equivalents, Exceptional Items, CWIP 275 540 719 833 808 1,604 2,221 11.5% 15.9% 13.8% 13.5% 11.3% 15.9% 24.5% FY20 FY21 FY22 FY23 FY24 FY25 9MFY26 PAT (₹ Mn) PAT Margin (%) PAT and PAT Margins (₹ Mn & %) 27.2% 30.7% 19.2% 19.7% 12.6% 19.1% 31.6% 24.6% 32.4% 13.8% 18.7% 11.4% 15.1% 26.3% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0% FY20 FY21 FY22 FY23 FY24 FY25 9MFY26 ROCE ROE Returns Profile# 97% 95% 83% 84% 79% 85% 86% 3% 5% 18% 16% 21% 15% 14% FY20 FY21 FY22 FY23 FY24 FY25 9MFY26 Pharma Intermediates Specialty Chemicals Revenue – by Business Verticals (%) 410 802 1,052 1,227 1,285 2,321 2,969 17.1% 23.5% 20.2% 19.9% 17.9% 23.0% 32.7% FY20 FY21 FY22 FY23 FY24 FY25 9MFY26 EBITDA (₹ Mn) EBITDA Margin (%) EBITDA and EBITDA Margins (₹ Mn. & %) Note: PAT for FY24 is adjusted for Exceptional Items (%)
Page 6
Earnings Presentation | January 2026 Financial Performance over the years - Profit and Loss 6 Particulars (₹ Mn.) FY21 FY22 FY23 FY24 FY25 9MFY26 Revenue from Operations 3,406 5,201 6,167 7,175 10,069 9,066 Other Income 14 28 43 75 169 305 Total Income 3,420 5,229 6,210 7,250 10,238 9,371 Cost of materials consumed 1,749 2,823 3,459 4,402 5,698 4,113 Changes in inventories of finished goods, traded goods and work-in- progress 48 (95) (150) (285) (176) (98) Employee benefits expenses 210 414 488 631 837 843 Finance cost 56 64 24 59 62 21 Depreciation and amortisation expenses 42 101 123 161 266 264 Other expenses 598 1,008 1,144 1,142 1,390 1,239 Total Expense 2,703 4,315 5,088 6,110 8,077 6,382 Profit before tax and exceptional items 717 914 1,122 1,140 2,162 2,989 Exceptional profit / (loss) - - - (321) - - Tax expense 177 195 289 332 557 768 Profit for the year 540 719 833 487 1,604 2,221
Page 7
Earnings Presentation | January 2026 Financial Performance over the years - Balance Sheet 7 Assets (₹ Mn.) FY21 FY22 FY23 FY24 FY25 H1 FY26 Property, plant and equipment 1,422 1,584 1,844 3,229 4,629 5,698 Right of use assets 184 194 374 372 424 498 Capital work-in-progress 2 30 255 1,254 1,303 1,519 Goodwill - - 203 568 568 733 Other intangible assets 257 267 211 103 83 73 Investments 14 17 17 2 2 2 Other financial assets 27 108 65 26 49 69 Current tax assets (net) - 49 32 25 2 - Other non-current assets 64 97 129 447 517 465 Total non-current assets 1,970 2,346 3,130 6,026 7,577 9,058 Inventories 604 1,122 1,192 1,567 1,799 1,910 Trade receivables 1,207 1,637 2,303 2,064 2,905 2,915 Cash and cash equivalents 27 103 305 297 1,852 1,725 Other bank balances - 893 281 236 637 682 Loans 3 6 13 16 22 21 Other current assets 321 481 445 753 701 646 Total current assets 2,162 4,291 4,571 4,958 7,918 7,899 Total assets 4,133 6,589 7,669 10,959 15,493 16,956 Equity and Liabilities (₹ Mn.) FY21 FY22 FY23 FY24 FY25 H1 FY26 Shareholder's equity 1,669 5,223 5,939 6,828 13,201 14,391 Financial Liabilities 726 6 6 1,136 48 81 Provisions 44 4 7 13 25 33 Deferred tax liabilities (net) 33 63 88 130 196 259 Total non-current liabilities 803 73 101 1,280 269 374 Borrowings 640 3 30 1,030 82 2 Trade payables 848 1,184 1420 1,346 1,560 1,492 Other current liabilities 151 46 64 344 135 344 Provisions 10 60 114 132 245 321 Current tax liabilities (net) 11 - - - - 33 Total current liabilities 1,660 1,293 1,628 2,852 2,022 2,192 Total liabilities 2,463 1,366 1,730 4,131 2,292 2,566 Total equity and liabilities 4,133 6,589 7,669 10,959 15,493 16,956
Page 8
Earnings Presentation | January 2026 Promoters 32.7% MF 15.1% Other DII 6.6% FII 16.7% Others 29.0% Shareholder Information 8 Source: BSE Shareholding as on 31st December 2025 Share Information as on 31st December 2025 Source: NSE NSE Ticker ACUTAAS BSE Ticker 543349 Market Cap (₹ Cr.) 13,958 Shares Outstanding 8,18,71,122 3M ADTV (Shares) 3,50,109 3M ADTV (₹ Cr.) 59.2 Industry Specialty Chemicals
Page 9
Earnings Presentation | January 2026 Safe Harbor 9 The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Acutaas Chemicals Ltd.
Page 10
Contact Us For more information please contact: www.acutaas.com www.acutaas.com Acutaas Chemicals Limited Ekta Srivastava Company Secretary & Compliance Officer cs@acutaas.com Rahul Thakur Senior Manager – Investor Relations Rahul.thakur@acutaas.com